EUCTR2006-004775-35-GB进行中（未招募）1 期
The Effect of Treating Patients with Anaemia in Diabetic Nephropathy to different target haemoglobin levels with Epoetin Beta - Epoetin Beta in AD
Barts and the London NHS Trust0 个研究点目标入组 0 人开始时间: 2006年11月22日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1) Male and female patients with Diabetic Nephropathy and Chronic Kidney Disease III and IV
- •2) Age >18 years and < 80 years
- •3) Haemoglobin <11.5g/dl
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1) Current treatment with an ESA
- •2) Uncontrolled Hypertension
- •3) Congestive Cardiac Failure
- •4) History of Seizures
- •5) History of thrombotic episodes
- •6) Pregnancy
- •6) Lactation
- •8) Presence of systemic disease, infection or inflammatory conditions
- •9) Hepatic Insufficiency
- •10) Active Hepatitis
- •11) Uncontrolled hypothyroidism
- •12) Chronic Alcoholism
- •13) Known hypersensitivity to the active substance in the cartridge or benzoic acid
- •14) Known sensitivity to Epoetin Beta
研究者
相似试验
已完成
不适用
The effect of treating patients with anaemia in diabetic nephropathy to different target haemoglobin levels with epoetin betaAnaemia in diabetic nephropathyHaematological DisordersAnaemiaISRCTN66395033Barts and the London NHS Trust (UK)160
招募中
1 期
Phase 2 Study of Luspatercept in Adults and Adolescents with Alpha (a)-thalassemiaAlpha (a)-thalassemiaMedDRA version: 20.1Level: LLTClassification code: 10054659Term: Thalassemia alpha Class: 10010331CTIS2022-502328-35-00Celgene Corp.177
招募中
不适用
An influence of therapy agaist renal anemia and secondary hyperparathyroidism on iron dysregulation in patients with chronic kidney diseaseChronic kidney diseaseJPRN-UMIN000011613Hyogo College of Medicine100
暂停
不适用
Examination of the effect of improving anemia / taste disorder by administration of zinc supplementation to chronic kidney disease exhibiting hypozincemiaJPRN-UMIN000031655Juntendo University500
进行中（未招募）
不适用
Subcutaneous Treatment of Anemia in patients with a GFR Below 45 ml/min/1.73m2 through Injections with Mircera as low frequent as Once monthly - STABILOChronic renal anaemiaMedDRA version: 9.1Level: PTClassification code 10058116Term: <Manually entered code. Term in E.1.1>EUCTR2007-005528-34-BE.V. Roche S.A.